Featured ArticlesPsoriasis

Topical Cannabinoids for the Management of Psoriasis Vulgaris: Report of a Case and Review of the Literature

By August 27, 2020No Comments

Featured Article

Featured Article

The interest in use of medical cannabis for chronic dermatologic conditions such as psoriasis, eczema, and acne has been growing mostly owing to rapidly emerging decriminalization across the country and impressive commercially driven popularization of a variety of cannabinoid preparations including topical forms such as creams, salves, lotions, lubricants, and many others.

Read more

This report details a case of a young man with psoriasis managed with topical cannabinoids.

Adam J. Friedman MD, Kimia Momeni BS, Mikhail Kogan MD

 

The interest in use of medical cannabis for chronic dermatologic conditions such as psoriasis, eczema, and acne has been growing mostly owing to rapidly emerging decriminalization across the country and impressive commercially driven popularization of a variety of cannabinoid preparations including topical forms such as creams, salves, lotions, lubricants, and many others.

However, while the market is exponentially growing, the rate at which mechanistic and clinical evidence supporting the use of cannabinoids in a litany of diseases is significantly slower. In fact, Robinson et al highlighted significant gaps in dermatologists understanding of the biology of cannabinoids and comfort with this space, further highlighting the great need to disseminate information throughout the medical community.

Along this vein, we present a case of a young man with psoriasis managed with topical cannabinoids.

View Case Study Now
Article Cited in this Post

You May Also Like

From the Vault: Integrated Short-Term and Long-Term Efficacy of Topical Clascoterone Cream 1% in Patients Aged 12 Years or Older With Acne Vulgaris

| Acne, Featured Articles, Latest News, The Latest | No Comments
Clascoterone Keeps Gaining Ground in Acne Two identical Phase 3 trials (plus a long‑term extension) randomized patients ≥12 years with moderate‑to‑severe acne to twice‑daily clascoterone 1% cream or vehicle for…
Journal of Drugs in Dermatology JDD Article About Microneedling Combined With Drugs and Stem Cells for Treating Androgenetic Alopecia

Microneedling Combined With Drugs and Stem Cells for Treating Androgenetic Alopecia

| Alopecia, Featured Articles, Latest News, The Latest | No Comments
Small Channels, Smarter Delivery -  A Practical Boost For Topical And Regenerative Approaches Microneedling is proving to be a low‑risk, clinic-friendly way to enhance topical therapies (most consistently 5% minoxidil, now…
Journal of Drugs in Dermatology JDD Article About The Prevalence of Dupilumab-Associated Adverse Events Among Black and African American Adult Patients With Atopic Dermatitis: A Retrospective Chart Review

The Prevalence of Dupilumab-Associated Adverse Events Among Black and African American Adult Patients With Atopic Dermatitis: A Retrospective Chart Review

| Atopic Dermatitis, Featured Articles, Latest News, The Latest | No Comments
Dupilumab in Diverse Skin — Are Adverse Events Really the Same? Atopic dermatitis isn’t one-size-fits-all: chronic type 2 inflammation, barrier dysfunction, and S. aureus colonization are core features, but presentation…

Leave a Reply